文献速递其他结缔组织病

ianalumab靶向BAFF受体并增强ADCC治疗原发性干燥综合征的II期研究

Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity.
PubMed 文献 · Ann Rheum Dis · 2019-03-02

这项双盲、安慰剂对照、单中心II期研究纳入ESSDAI≥6的活动性原发性干燥综合征患者,随机接受ianalumab单次输注3 mg/kg(n=6)、10 mg/kg(n=12)或安慰剂(n=9)。结果显示ianalumab在主要临床结局ESSDAI及所有次要临床结局上均较安慰剂组呈现相似的趋势性治疗获益,单次输注后出现快速、持久且深刻的B细胞耗竭,不良事件主要限于输注后24小时内的轻至中度输注反应。

要点

  • 单次ianalumab输注在活动性pSS中呈现ESSDAI及多项次要结局优于安慰剂的趋势。
  • 两种剂量均引起快速、深刻且持久的B细胞耗竭,血清Ig轻链下降并于研究终点恢复基线。
  • 不良事件主要限于给药后24小时内的轻至中度输注反应。

核心结论

  • 这项单剂量研究的结果提示,ianalumab通过强效且持久的B细胞耗竭可能为原发性干燥综合征患者提供治疗获益,且无重大副作用。

研究设计与样本

  • 双盲、安慰剂对照、单中心II期研究,纳入ESSDAI≥6的原发性干燥综合征患者,随机接受ianalumab单次输注3 mg/kg(n=6)、10 mg/kg(n=12)或安慰剂(n=9)。
  • 结局在基线及第6、12、24周盲法评估,研究终点(EoS)在B细胞数量恢复后揭盲评估。

主要发现

  • ianalumab在主要临床结局ESSDAI及所有次要临床结局(ESSPRI、多维疲劳量表、SF-36、医生与患者整体评估)上均较安慰剂组呈现相似的趋势性治疗获益。
  • 单次输注ianalumab任一剂量后均出现快速、深刻且持久的B细胞耗竭。
  • 血清Ig轻链下降,并在研究终点恢复至基线水平。
  • 较高剂量组的部分临床结局变化持续至研究终点。
  • 不良事件主要限于ianalumab给药后24小时内的轻至中度输注反应。

关键数值与推荐

  • 纳入标准为原发性干燥综合征且ESSDAI≥6。
  • 随机分组为ianalumab 3 mg/kg(n=6)、10 mg/kg(n=12)或安慰剂(n=9),均为单次输注。
  • 临床结局包括ESSDAI、ESSPRI、唾液流率、眼染色评分、医生整体评估及患者疲劳与总体生活质量评估。

临床怎么用

  • 结果支持在活动性原发性干燥综合征中进一步评估ianalumab的B细胞耗竭策略,但当前为单中心单剂量II期研究,尚不能直接指导临床用药。
  • 用药后需关注给药24小时内的输注反应,并监测B细胞数量与血清Ig轻链变化。

局限性

  • 研究为单中心、单剂量设计,样本量小(ianalumab 3 mg/kg组n=6、10 mg/kg组n=12、安慰剂组n=9)。
  • 主要与次要临床结局均呈现趋势性获益,未报告正式统计学显著性检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of ianalumab (VAY736), a B cell-depleting, B cell activating factor receptor-blocking, monoclonal antibody, in patients with active primary Sjögren's syndrome (pSS) in a double-blind, placebo-controlled, phase II, single-centre study. METHODS: Patients with pSS, EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) ≥6, were randomised to ianalumab single infusion at either 3 mg/kg (n=6), 10 mg/kg (n=12) or placebo (n=9). Outcomes were measured blinded at baseline and weeks 6, 12, 24, and unblinded at end of study (EoS) when B cell numbers had recovered. Clinical outcomes included ESSDAI, EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI), salivary flow rate, ocular staining score, physician global assessment and patient assessments of fatigue and general quality of life. Laboratory-based measures included circulating leucocyte subsets and markers of B cell activity. RESULTS: A similar trend showing positive therapeutic effect by ianalumab was observed across the primary clinical outcome (ESSDAI) and all secondary clinical outcomes (ESSPRI, Multidimensional Fatigue Inventory, Short Form-36, global assessments by physician and patient) versus the placebo-treated group. Rapid and profound B cell depletion of long-lasting duration occurred after a single infusion of ianalumab at either dose. Serum Ig light chains decreased, with return to baseline levels at EoS. Changes in some clinical outcomes persisted through to EoS in the higher dose group. Adverse effects were largely limited to mild to moderate infusion reactions within 24 hours of ianalumab administration. CONCLUSIONS: Overall results in this single-dose study suggest potent and sustained B cell depletion by ianalumab could provide therapeutic benefits in patients with pSS without major side effects.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Dörner T, Posch MG, Li Y, et al. Treatment of primary Sjögren's syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Ann Rheum Dis. 2019. PMID: 30826774. doi:10.1136/annrheumdis-2018-214720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。